Verastem, Inc. amends debt purchase agreement
Verastem, Inc. filed an amendment to its Note Purchase Agreement with its bondholders, the third amendment to the agreement.
View filing at SEC.gov →4 most recent filings and news items mentioning VSTM. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/VSTM/news?limit=20"
Pull VSTM filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayVerastem, Inc. filed an amendment to its Note Purchase Agreement with its bondholders, the third amendment to the agreement.
View filing at SEC.gov →Verastem Oncology exceeded expectations with $25.1M revenue and reported the first patient dosed across three registration-directed VS-7375 Phase 2 trials. The company also secured a $75M non-dilutive royalty financing, extending its cash runway into late 2027.
View filing at SEC.gov →Verastem hosted an R&D update call discussing the KRAS G12D inhibitor VS-7375. This information is relevant for investors assessing the company's potential pipeline opportunities in the oncology space.
View filing at SEC.gov →Verastem Oncology announced positive updated results from RAMP 205 evaluating avutometinib plus defactinib combined with standard chemotherapy in first-line metastatic pancreatic cancer, showing an 86% overall survival rate at 6 months and 52% objective response rate. The encoura
View filing at SEC.gov →